NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory disease
AssigneeSecarna Pharmaceuticals GmbH & Co. KG
InventorsMarta Lucia DE LOS REYES, Frank JASCHINSKI, Sven MICHEL, Anna URI
Life of this patent
Estimating the term…
Abstract
The present invention refers to oligonucleotide consisting of 12 to 20 nucleotides comprising at least one modified nucleotide hybridizing with a nucleic acid sequence of NLR family pyrin domain containing 3 (NLRP3) and a pharmaceutical composition 5 comprising such oligonucleotide together with a pharmaceutically acceptable carrier, excipient and/or dilutant to inhibit the expression of NLRP3 for example for preventing and/or treating an inflammatory disease.
Claims15
Oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO. 59, SEQ ID NO. 335, SEQ ID NO. 297, and SEQ ID NO. 133 comprising at least one modified nucleotide, hybridizing with a nucleic acid sequence of a NLR family pyrin domain containing 3 (NLRP3) of human SEQ ID NO. 1 and/or human SEQ ID NO. 2 resulting in a reduction of the level of NLRP3, NLRP3 mRNA, NLRP3 pre-mRNA or a combination thereof.
Dependencies are inferred from the claim text.